Przejdź do treści

Let’s get it started!  

On December 2nd, 2022, Doto Medical Ltd. was registered!!! Our goal is to accelerate the commercialization of a strategic PB103 aptamer project. 

The project focuses on the development of a medical device in cooperation with the Dutch Relitech BV company. The device will be used in an innovative targeted dialysis based on aptamers, used in patients suffering from chronic kidney disease [CKD]. 

The proposed solution aims to increase the effectiveness of dialysis in terms of clinical parameters that do not significantly improve during standard dialysis, and thus prolong survival and improve the quality of life of patients. CKD is a diseases that affects up to 75 million patients worldwide, and the average survival time since the start of dialysis therapy is about 5 years. This represents a significant unmet medical need, as well as a wide target market estimated at around $100 billion. 

Additionally, the company will be supported by Clairfield Partners LLC. The CP experience and reputation, makes it easier to establish contacts with potential recipients of technologies from the dialysis industry, and CP’s advice will increase the probability of successful commercialization.